Last reviewed · How we verify

NCT06710795: AFFIX

AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair

Active, enrolled NA Last updated 16 April 2026
What this trial tests

NA trial testing MaxTack™ Motorized Fixation Device in Ventral Hernia in 35 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
16 June 2025
Primary endpoint
23 March 2026
7 May 2027

Quick facts

Lead sponsorMedtronic - MITG
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment35
Start date16 June 2025
Primary completion23 March 2026
Estimated completion7 May 2027
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medtronic - MITG — full company profile →

Who can join

18 and older, any sex, with Ventral Hernia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Medtronic is sponsoring and funding the AFFIX study, a prospective, post-market, multicenter, nonrandomized, single-arm, interventional clinical study. The purpose of this study is to evaluate the performance and safety of the MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair procedures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ventral Hernia

Currently open trials in the same condition.

Other Medtronic - MITG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06710795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing